 BioLife Solutions, Inc. NASDAQ: BLFS BioLife or the Company, a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced estimated preliminary revenue for the second quarter of 2020 of 9.6 million to 9.8 million, representing 43 to 46 growth over the same quarter in 2019. 